ReviewCurrent hypertension reports2007
Dual effects of RAS blockade on blood pressure and podocyte function.
Review in Current hypertension reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Clinical study on Yishen Qufeng Shengshi Recipe () for glomerular proteinuria patients: A randomized controlled trial.Chinese journal of integrative medicine · 2018Trial
- Unveiling Angiotensin II and Losartan-Induced Gene Regulatory Networks Using Human Urine-Derived Podocytes.International journal of molecular sciences · 2023Article
- Tetrahydrocurcumin Ameliorates Kidney Injury and High Systolic Blood Pressure in High-Fat Diet-Induced Type 2 Diabetic Mice.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Wnt/β-catenin regulates blood pressure and kidney injury in rats.Biochimica et biophysica acta. Molecular basis of disease · 2019Article
- Angiotensin II induces calcium/calcineurin signaling and podocyte injury by downregulating microRNA-30 family members.Journal of molecular medicine (Berlin, Germany) · 2017Article
- Mesenchymal Stem Cell-Based Therapies against Podocyte Damage in Diabetic Nephropathy.Tissue engineering and regenerative medicine · 2017Review
- Multiple genes of the renin-angiotensin system are novel targets of Wnt/β-catenin signaling.Journal of the American Society of Nephrology : JASN · 2015Article
- A novel mouse model of advanced diabetic kidney disease.PloS one · 2014Article
- Calmodulin-dependent protein kinase II/cAMP response element-binding protein/Wnt/β-catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria.The Journal of biological chemistry · 2013Article
- Endothelin and the podocyte.Clinical kidney journal · 2012Review
- Obesity-related glomerulopathy and podocyte injury: a mini review.Frontiers in bioscience (Elite edition) · 2012Review
- Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.The American journal of pathology · 2011Article
- Podocytopathy in diabetes: a metabolic and endocrine disorder.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2011Review
- Podocyte dysfunction in aging--related glomerulosclerosis.Frontiers in bioscience (Scholar edition) · 2011Review
- Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes.Current diabetes reviews · 2011Review
- Toward the development of podocyte-specific drugs.Kidney international · 2010Review
- Proteinuria: an enzymatic disease of the podocyte?Kidney international · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is no question about the contributory risk of hypertension in morbidity and mortality from cardiovascular (CV) disease and chronic kidney disease (CKD). Another independent risk factor for CV disease and CKD is proteinuria, which is most commonly caused by dysfunction of the kidney glomerular filter, in particular of the podocyte. Podocytes are highly differentiated pericyte-like cells that are essential to normal kidney function. Moreover, loss of podocytes is a hallmark of diabetic and nondiabetic progressive CKD. Recent data point to an important role for the renin-angiotensin system (RAS) and calcium signaling in the structural and functional integrity of podocytes. Given this scenario, it is desirable to treat hypertension with agents targeting the RAS, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (Ang II) type 1-receptor blockers (ARB). These agents have proven effects on lowering blood pressure (BP) and can reduce podocyte injury. Here we review the dual effects of RAS blockade on BP and on podocyte function and emphasize BP-dependent and BP-independent effects of this regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.